Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedA general NIH notice about the terminology transition appears above the ClinicalTrials.gov 403 error page. The displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe footer revision number was updated from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check32 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study details with an access-denied message and signaling that the study record cannot be viewed at the moment.SummaryDifference20%

- Check39 days agoChange DetectedThe page’s revision identifier was updated from v3.6.6 to v3.7.0, signaling a newer edition of the page content. This update is a metadata change that does not modify the study details.SummaryDifference0.0%

- Check53 days agoChange DetectedA new page revision tag (v3.6.6) appears, replacing the previous v3.6.5. This signals an update to the page's metadata rather than any changes to the study content.SummaryDifference0.0%

- Check74 days agoChange DetectedRevision label updated to v3.6.5, replacing the previous v3.6.4. This reflects a small maintenance update to the site's revision history and does not change the study content.SummaryDifference0.0%

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.